Hydroxyurea has 43 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 34 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Didanosine, Didanosine And Stavudine, Articaine Hydrochloride And Epinephrine. Patients taking Hydroxyurea should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 43
- Contraindicated
- 2
- Major
- 34
- Moderate
- 7
Contraindicated (2)
- Hydroxyurea + Didanosine— Avoid combination of hydroxyurea, didanosine, and stavudine due to fatal hepatic events and hepatotoxicity/hepatic failu…
- Hydroxyurea + Didanosine And Stavudine— Avoid this combination. Fatal hepatic events and severe peripheral neuropathy reported most often with hydroxyurea, dida…
Major (34)
- Hydroxyurea + Articaine Hydrochloride And Epinephrine— Increased risk of methemoglobinemia when concurrently exposed to articaine.
- Hydroxyurea + Articaine Hydrochloride And Epinephrine Bitartrate— Increased risk of developing methemoglobinemia when concurrently exposed to this antineoplastic agent.
- Hydroxyurea + Benzocaine, Butamben, And Tetracaine Hydrochloride— Increased risk of methemoglobinemia when concurrently exposed to this antineoplastic oxidizing agent with local anesthet…
- Hydroxyurea + Bupivacaine And Meloxicam— Increased risk of methemoglobinemia when local anesthetics are used concomitantly with antineoplastic agents.
- Hydroxyurea + Bupivacaine Hydrochloride— Increased risk of methemoglobinemia when concurrently exposed with bupivacaine.
- Hydroxyurea + Dexamethasone Sodium Phosphate, Lidocaine Hydrochloride, Povidine Iodine— Antineoplastic agent associated with increased methemoglobinemia risk when used with ropivacaine.
- Hydroxyurea + Exagamglogene Autotemcel— Discontinue at least 8 weeks prior to start of mobilization and conditioning. No experience with use after CASGEVY infus…
- Hydroxyurea + Ganciclovir Sodium— Associated with myelosuppression or nephrotoxicity; coadministration should be considered only if potential benefits out…
- Hydroxyurea + Lidocaine— Increased risk of methemoglobinemia when used concurrently with lidocaine.
- Hydroxyurea + Lidocaine 5%— Antineoplastic agent that may cause methemoglobinemia when used concomitantly with lidocaine patch 5%.
- Hydroxyurea + Lidocaine And Capsaicin— Antineoplastic agent that increases risk of methemoglobinemia when used concurrently with lidocaine and capsaicin patch.
- Hydroxyurea + Lidocaine And Prilocaine— Antineoplastic agent; increased risk of methemoglobinemia when concurrently exposed.
- Hydroxyurea + Lidocaine Hydrochloride— Increased risk of methemoglobinemia when used concurrently with lidocaine hydrochloride.
- Hydroxyurea + Lidocaine Hydrochloride And Epinephrine Bitartrate— Antineoplastic agent associated with increased methemoglobinemia risk when used concurrently.
- Hydroxyurea + Lidocaine Hydrochloride And Hydrocortisone Acetate— Increased risk of methemoglobinemia when local anesthetic is concurrently exposed to antineoplastic agents.
- Hydroxyurea + Lidocaine Hydrochloride Monohydrate— Concurrent exposure increases risk of methemoglobinemia in patients administered local anesthetics.
- Hydroxyurea + Lidocaine Patch 5%— Increased risk of methemoglobinemia; antineoplastic agents associated with methemoglobinemia when used with local anesth…
- Hydroxyurea + Lidocaine, Isopropyl Alcohol— Increased risk of methemoglobinemia when used with lidocaine.
- Hydroxyurea + Lidocaine, Menthol— Increased risk of methemoglobinemia when lidocaine is concurrently exposed to antineoplastic agents.
- Hydroxyurea + Lidothol Patch— Increased risk of methemoglobinemia when local anesthetics are concurrently exposed to antineoplastic agents.
- Hydroxyurea + Lovotibeglogene Autotemcel— Discontinue 2 months prior to mobilization and 2 days prior to conditioning. Interaction with mobilization process and L…
- Hydroxyurea + Marcaine, Lidocaine, Kenalog, Povidone Iodine— Increased risk of methemoglobinemia when concurrently exposed to antineoplastic agents.
- Hydroxyurea + Marnetegragene Autotemcel— Do not take for one month prior to mobilization or expected duration for elimination, and until all apheresis cycles com…
- Hydroxyurea + Measles Vaccine— Concomitant use may potentiate vaccine virus replication and increase adverse reactions. May result in severe infections…
- Hydroxyurea + Mepivacaine Hydrochloride— Concurrent exposure increases risk of methemoglobinemia in patients administered mepivacaine.
- Hydroxyurea + Prilocaine Hcl And Epinephrine— Increased risk of methemoglobinemia when prilocaine is concurrently exposed to hydroxyurea.
- Hydroxyurea + Prilocaine Hydrochloride— Increased risk of methemoglobinemia when used concurrently with prilocaine.
- Hydroxyurea + Ropivacaine Hydrochloride— Increased risk of developing methemoglobinemia when concurrently exposed to hydroxyurea.
- Hydroxyurea + Stavudine— Fatal and nonfatal pancreatitis, hepatotoxicity with hepatic failure, and severe peripheral neuropathy reported in HIV p…
- Hydroxyurea + Triamcinolone Acetonide— Increased risk of methemoglobinemia when concurrently exposed.
- Hydroxyurea + Triethanolamine Salicylate— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Hydroxyurea + Trubrexa Patch Er— Increased risk of methemoglobinemia when used with Trubrexa Transdermal Patch.
- Hydroxyurea + Valganciclovir— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
- Hydroxyurea + Valganciclovir Hydrochloride— Co-administration with valganciclovir should be considered only if potential benefits outweigh risks due to potential fo…
Moderate (7)
- Hydroxyurea + Bupivacaine— May increase risk of methemoglobinemia when concurrently exposed with bupivacaine.
- Hydroxyurea + Bupivacaine Hydrochloride And Epinephrine Bitartrate— Increased risk of methemoglobinemia when concurrently exposed.
- Hydroxyurea + Bupivacaine Hydrochloride With Dextrose— Increased risk of developing methemoglobinemia when concurrently exposed.
- Hydroxyurea + Ganciclovir— Associated with myelosuppression or nephrotoxicity. Coadministration considered only if benefits outweigh risks.
- Hydroxyurea + Lidocaine And Tetracaine— Antineoplastic agent that increases risk of methemoglobinemia when used concomitantly with lidocaine and tetracaine.
- Hydroxyurea + Marcaine, Kenalog, Povidone Iodine— Increased risk of methemoglobinemia when concurrently exposed to antineoplastic agents with bupivacaine.
- Hydroxyurea + Penicillin G Benzathine And Penicillin G Procaine— Increased risk of methemoglobinemia when concurrently exposed with local anesthetics (procaine is a component of this dr…